Joel Cohen-Solal is a Principal Research Scientist at AbbVie, where he leads the Fc Biology Team, focusing on the innovative development of monoclonal antibody (mAb) therapies. With a robust background in autoimmunity and tumor immunology, Joel's expertise lies at the intersection of Fc/FcR biology and...
Joel Cohen-Solal is a Principal Research Scientist at AbbVie, where he leads the Fc Biology Team, focusing on the innovative development of monoclonal antibody (mAb) therapies. With a robust background in autoimmunity and tumor immunology, Joel's expertise lies at the intersection of Fc/FcR biology and immunogenicity, making him a pivotal figure in advancing therapeutic strategies for complex diseases. His current role involves the implementation and characterization of Fc mutations in biologics, where he employs cutting-edge techniques in Fc multiformat engineering to enhance the efficacy and safety profiles of therapeutic candidates.
Under Joel's leadership, the Fc Biology Team is dedicated to manipulating ITIM/ITAM signaling pathways to elucidate mechanisms of action (MOA) across various programs, including immunology, oncology, virology, and neurosciences. His work encompasses in vivo, ex vivo, and in vitro studies, providing comprehensive insights into the pharmacokinetics of biologics and their half-life in vivo. Joel's proficiency in flow cytometry, biochemistry, and molecular biology enables him to design and execute experiments that drive the understanding of how Fc modifications can influence therapeutic outcomes.
In addition to his technical skills, Joel is adept at grant writing, ensuring that his team's innovative projects receive the necessary funding to propel their research forward. His contributions are not only advancing AbbVie's pipeline but also shaping the future of biologic therapies in the broader pharmaceutical landscape. With a commitment to scientific excellence and a passion for translating research into impactful treatments, Joel Cohen-Solal continues to be a driving force in the field of immunotherapy.
